Helium crunch hits MRI ops; tariff refunds delayed 90 days
Supply Chain Pulse — 2026-04-12
Geopolitical tensions are choking helium supplies to U.S. healthcare facilities, threatening MRI operations just as imaging demand rebounds post-pandemic. The timing couldn't be worse: new compliance-driven tariffs are reshaping medical device costs while customs refund delays stretch to 90 days, and a $119 million antibiotic manufacturing deal signals Washington's push to reshore critical drug production. Supply chain resilience isn't just a buzzword anymore—it's becoming the difference between operational stability and crisis management.
Quick Hits
- Henry Schein Q1 2026 earnings report expected this week (Yahoo Finance)
- SpendMend appoints Paul Kappelman as board chairman (Business Wire)
- Epic launches illness tracking tool for health systems (Modern Healthcare)
- Hims & Hers reports data breach affecting customer contact info (Modern Healthcare)
- Claims denial rates continue rising, impacting provider revenue (Modern Healthcare)
Helium Supply Disruptions Hit Medical Imaging Operations
Geopolitical tensions have exposed critical vulnerabilities in helium supply chains, directly impacting MRI systems that require liquid helium for superconducting magnets. With limited global suppliers and no viable substitutes, facilities are facing potential imaging service disruptions at a time when diagnostic volumes are recovering. Supply chain managers should assess helium inventory levels and consider backup supplier agreements immediately.
Source: Healthcare Purchasing News
U.S. Awards Shionogi $119M for Domestic Antibiotic Production
The Japanese drugmaker's U.S. subsidiary secured the contract to manufacture cefiderocol, a critical antibiotic effective against bacterial biothreats and multi-drug resistant infections. This represents a significant federal investment in domestic pharmaceutical manufacturing capacity, potentially reducing reliance on overseas antibiotic suppliers. Procurement teams should monitor how this reshoring trend affects pricing and availability of other critical antimicrobials.
Source: Healthcare Purchasing News
New Trade Policies Target Medical Device Underreporting
Revised tariff structures now calculate duties on branded drugs and medical devices based on actual U.S. sales prices rather than declared import values, aimed at curbing underreporting and incentivizing domestic production. This compliance-driven approach could significantly increase costs for imported medical supplies, particularly high-value devices where price discrepancies are common. Finance teams should review import documentation processes and budget for potential cost increases on foreign-sourced equipment.
Source: Healthcare Purchasing News
Customs Bureau Extends Tariff Refund Timeline to 90 Days
CBP's new refund system will take 60-90 days to process tariff returns, double the previously promised 45-day timeline. This extended cash flow impact comes as healthcare organizations are already managing tighter margins and increased compliance costs from new trade policies. CFOs should factor these delays into working capital planning, especially for high-volume importers of medical supplies.
Source: Supply Chain Dive - Healthcare
Orlando Health Expands Footprint with Alabama System Acquisition
The Florida-based health system's expansion into Alabama represents continued consolidation in the Southeast market, likely creating new procurement synergies and standardization opportunities. Larger health systems typically leverage enhanced purchasing power to negotiate better device and pharmaceutical contracts. Vendors serving the region should prepare for potential contract renegotiations and standardization requirements.
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe